Education
About Us
Working with TipRanks
Follow Us
Harmony Biosciences Holdings, Inc. (HRMY)
:HRMY
HRMY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$28.14 - $41.61
Previous CloseN/A
Volume87.33K
Average Volume (3M)761.01K
Market Cap
$1.90B
Enterprise Value$1.77B
Total Cash (Recent Filing)-$83.52M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)13.2
Beta1.55
Next Earnings
May 06, 2025EPS Estimate
0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.51
Shares Outstanding57,345,610
10 Day Avg. Volume775,546
30 Day Avg. Volume761,012
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)N/A
Price to Sales (P/S)2.83
Price to Cash Flow (P/CF)6.70
P/FCF Ratio6.40
Enterprise Value/Market Cap0.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.84
Enterprise Value/Ebitda8.66
Forecast
1Y Price Target
$54.00Price Target Upside61.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Harmony Biosciences Holdings News
PremiumCompany Announcements
Harmony Biosciences Appoints New Chief Commercial Officer
PremiumCompany Announcements
Harmony Biosciences Earnings Call Highlights Growth and Challenges
PremiumCompany Announcements
Harmony Biosciences Reports Strong 2024 Financial Results---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceNon-GAAP EPS exceeded expectations, highlighting strong financial performance.
LeadershipThe new chief commercial officer, Adam Zaeske, is seen as a proven leader with 25 years of experience, including his work with orexin-based candidates for orphan sleep disorders.
Patent SettlementThe announcement of a patent settlement with a first generic challenger sets a 2030 generic Wakix launch, which is seen as a positive development for HRMY.
Bears Say
Generic CompetitionThe company did announce a Wakix patent settlement for 2030 entry but six other generic challengers remain.
Pipeline ChallengesLast month's setback for pitolisant for idiopathic hypersomnia/IH still stings, leading to reset revenue expectations for HRMY.
Pipeline CreditWe look for upcoming pivotal data from Harmony’s Zygel in Fragile X Syndrome, although we assign no pipeline credit given the prior study failed to show benefit.
---
Ownership Overview
26.59% Insiders
21.38% Mutual Funds
25.47% Other Institutional Investors
1.26% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HRMY FAQ
What was Harmony Biosciences Holdings, Inc.’s price range in the past 12 months?
Harmony Biosciences Holdings, Inc. lowest stock price was $28.14 and its highest was $41.61 in the past 12 months.
What is Harmony Biosciences Holdings, Inc.’s market cap?
Harmony Biosciences Holdings, Inc.’s market cap is $1.90B.
When is Harmony Biosciences Holdings, Inc.’s upcoming earnings report date?
Harmony Biosciences Holdings, Inc.’s upcoming earnings report date is May 06, 2025 which is in 37 days.
How were Harmony Biosciences Holdings, Inc.’s earnings last quarter?
Harmony Biosciences Holdings, Inc. released its earnings results on Feb 25, 2025. The company reported $0.85 earnings per share for the quarter, beating the consensus estimate of $0.734 by $0.116.
Is Harmony Biosciences Holdings, Inc. overvalued?
According to Wall Street analysts Harmony Biosciences Holdings, Inc.’s price is currently Undervalued.
Does Harmony Biosciences Holdings, Inc. pay dividends?
Harmony Biosciences Holdings, Inc. does not currently pay dividends.
What is Harmony Biosciences Holdings, Inc.’s EPS estimate?
Harmony Biosciences Holdings, Inc.’s EPS estimate is 0.63.
How many shares outstanding does Harmony Biosciences Holdings, Inc. have?
Harmony Biosciences Holdings, Inc. has 57,345,610 shares outstanding.
What happened to Harmony Biosciences Holdings, Inc.’s price movement after its last earnings report?
Harmony Biosciences Holdings, Inc. reported an EPS of $0.85 in its last earnings report, beating expectations of $0.734. Following the earnings report the stock price went up 8.163%.
Which hedge fund is a major shareholder of Harmony Biosciences Holdings, Inc.?
Currently, no hedge funds are holding shares in HRMY
---
Harmony Biosciences Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.00 (61.92% Upside)
$54.00 (61.92% Upside)
Blogger Sentiment
Bullish
HRMY Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 61.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $278.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-1.16%
12-Months-Change
Fundamentals
Return on Equity
25.84%
Trailing 12-Months
Asset Growth
23.14%
Trailing 12-Months
Company Description
Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
---
HRMY Company Deck
---
HRMY Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong performance in terms of revenue growth and patient base expansion for Harmony Biosciences. Significant advancements in their pipeline, including multiple ongoing and upcoming Phase 3 trials, highlight a solid strategy for future growth. However, the rejection of the Pitolisant sNDA and challenges in clinical trials for idiopathic hypersomnia present notable setbacks. Despite these challenges, the company's financial stability and strategic moves, such as the generic settlement, contribute to an overall positive outlook.Read More>---
HRMY Stock 12 Month Forecast
Average Price Target
$54.00
▲(61.92% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Jazz Pharmaceuticals
―
Supernus Pharmaceuticals
―
Xenon
―
Axsome Therapeutics
―
Best Analysts Covering HRMY
1 Year
---